by Elena Iemma | Dec 9, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth....
by Elena Iemma | Dec 6, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, a leader in biotechnology known for its advanced immunoinformatics tools, proudly announces its continued support for two nonprofits, Clínica Esperanza/Hope Clinic and GAIA Vaccine Foundation....
by Elena Iemma | Nov 19, 2024 | Blog
Talking out loud to myself (and about 7000 friends) It’s the time of year for gratitude As we approach the season of gratitude, I would like to THANK YOU, our colleagues in the immunogenicity space, who are “Science Forward”....
by Elena Iemma | Oct 29, 2024 | Blog
October is Rocking! Off to Amsterdam and Stockholm EpiVax Sets the Standards for the Generic Drug Industry Ok . . . that’s an over-the-top headline! But read the press release! It reflects our excitement about our new contract with FDA and, the statement is...
by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
